--- title: "The Penghua SSE Science and Technology Innovation Board 200 ETF is actively traded, with pharmaceuticals and commercial aerospace thriving against the trend" type: "News" locale: "en" url: "https://longbridge.com/en/news/281158990.md" description: "Today, the pharmaceutical and medical sectors, as well as commercial aerospace, are actively defying the trend. On March 30th, the \"Lijian No. 2\" remote one launch vehicle was successfully launched, igniting the commercial aerospace sector. Significant breakthroughs in CAR-T technology provide new ideas for cancer immunotherapy. Market sentiment remains cautious, with attention on the situation across the Taiwan Strait and earnings report disclosures. The latest quote for the Penghua SSE Science and Technology Innovation Board 200 ETF is 1.48 yuan, with good liquidity, averaging a daily transaction of 69.3284 million yuan over the past month. Among the constituent stocks of the Science and Technology Innovation Board 200 Index, the proportion of \"specialized, refined, distinctive, and innovative small giants\" reaches 69%" datetime: "2026-03-31T09:14:14.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/281158990.md) - [en](https://longbridge.com/en/news/281158990.md) - [zh-HK](https://longbridge.com/zh-HK/news/281158990.md) --- # The Penghua SSE Science and Technology Innovation Board 200 ETF is actively traded, with pharmaceuticals and commercial aerospace thriving against the trend Today, the pharmaceutical and medical sectors, as well as commercial aerospace, are actively defying the trend. On March 30, the "Li Jian No. 2" remote one carrier rocket was successfully launched, reigniting interest in the commercial aerospace sector. Additionally, a significant breakthrough in CAR-T technology has been made, with an international team involving Sweden's Karolinska Institute developing a new method to directly generate chimeric antigen receptor T cells in the body that can target and kill tumors, providing new ideas for cancer immunotherapy. Institutions point out that looking ahead, market sentiment remains cautious, and the market continues to fluctuate to digest external pressures. Current market pricing revolves around two core issues: first, the situation in the Taiwan Strait continues to cause disturbances in the short term; second, during the intensive earnings disclosure period, the market is more focused on the verification of performance. In the medium term, if external disturbances ease marginally and industrial catalysts continue to materialize, the Science and Technology Innovation Board 200 is expected to achieve a central upward trend. As of March 31, 2026, at 15:00, the Shanghai Stock Exchange Science and Technology Innovation Board 200 Index (000699) saw mixed performance among its constituent stocks, with Haitai New Light leading the gains at 14.34%, Aerospace Huanyu rising 5.97%, and Aerospace Software increasing 3.94%; Helin Micro-Nano led the declines. The latest quote for the Penghua Science and Technology Innovation Board 200 ETF (588240) is 1.48 yuan. In terms of liquidity, the Penghua Science and Technology Innovation Board 200 ETF saw a turnover of 11.5% during the day, with a transaction volume of 35.5994 million yuan. Looking at a longer time frame, as of March 31, the average daily transaction volume for the Penghua Science and Technology Innovation Board 200 ETF over the past month was 69.3284 million yuan. The Penghua Science and Technology Innovation Board 200 ETF closely tracks the Shanghai Stock Exchange Science and Technology Innovation Board 200 Index, which selects 200 securities with smaller market capitalization and better liquidity from the Science and Technology Innovation Board of the Shanghai Stock Exchange as samples. The Shanghai Stock Exchange Science and Technology Innovation Board 200 Index, along with the Shanghai Stock Exchange Science and Technology Innovation Board 50 Component Index and the Shanghai Stock Exchange Science and Technology Innovation Board 100 Index, constitutes the series of scale indices for the Science and Technology Innovation Board, reflecting the overall performance of securities of listed companies of different market capitalizations on the Science and Technology Innovation Board. The Penghua Science and Technology Innovation Board 200 ETF (588240) possesses three characteristics: "hard technology" logic, "small and micro-cap" opportunities, and "20% price fluctuation limit" elasticity. It gathers potential dark horses in science and technology, closely focusing on the direction of new productive forces, with the chip concept accounting for over 40%, commercial aerospace nearly 20%, and pharmaceuticals over 15%. As of the end of March 2026, the proportion of "specialized, refined, and innovative small giants" among the constituent stocks of the Science and Technology Innovation Board 200 Index reached 69%, demonstrating strong competitiveness and innovation capability. Data shows that as of February 27, 2026, the top ten weighted stocks in the Shanghai Stock Exchange Science and Technology Innovation Board 200 Index (000699) are Zhenlei Technology, Juguang Technology, Purun Co., Ltd., Jingzhida, Changguang Huaxin, Xinghuan Technology, Tengjing Technology, Xinqi Micro-Assembly, Jieput, and Dekeli, with the top ten weighted stocks accounting for a total of 16.78%. The Penghua Science and Technology Innovation Board 200 ETF (588240) has off-exchange connections (A: 023926; C: 023927) ### Related Stocks - [588240.CN](https://longbridge.com/en/quote/588240.CN.md) - [000699.CN](https://longbridge.com/en/quote/000699.CN.md) ## Related News & Research - [09:35 ETOpen Medicine Launches Ahead of ASCO, Introducing "Living Algorithms" for Real-Time Oncology Decision-Making](https://longbridge.com/en/news/286923155.md) - [17:16 ETPROCURE INTRODUCES NEW AWARENESS INITIATIVE TO EDUCATE PATIENTS ABOUT PROTON THERAPY](https://longbridge.com/en/news/286470195.md) - [Defence Therapeutics Enhances In-House ADC Development Platform with Expanded Analytical and Cellular Testing Capabilities | DTCFF Stock News](https://longbridge.com/en/news/286870222.md) - [Massive Bio and Just Worldwide to expand cancer trial access](https://longbridge.com/en/news/286630945.md) - [09:15 ETNewport Healthcare's 2025 Outcomes Report Demonstrates Significant Improvements in Teen and Young Adult Mental Health Following Treatment](https://longbridge.com/en/news/286920260.md)